drugset / Trial / NCT07518329
Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.
Non-randomizedSequentialOpen-labelTreatment
Summary
Phase 1 Open-Label Dose-Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ALA-101
Timeline
- Start
- 2026-04-01
- Primary completion
- 2030-03-31
- Completion
- 2030-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALA-101 | Cell therapy | 2e+07 cells | Intravenous |
| Subject | ALA-101 | Cell therapy | 5e+07 cells | Intravenous |
| Subject | ALA-101 | Cell therapy | 1.5e+08 cells | Intravenous |
| Subject | ALA-101 | Cell therapy | 3e+08 cells | Intravenous |
| Subject | ALA-101 | Cell therapy | 5e+08 cells | Intravenous |